Literature DB >> 8740117

beta-lactam antibiotics in the treatment of neuroborreliosis in children: preliminary results.

M M Millner1, G H Thalhammer, P Dittrich, K D Spork, M Brunner, A Georgopoulos.   

Abstract

In vitro beta-lactam antibiotics like ceftriaxone and penicillin G sodium have been shown to be active against Borrelia burgdorferi. Results of quantitative determinations of both antibiotic substances in the CSF for children are limited. Seventy-five children (median age 96 months, range 10 to 176 months) with probable or definite neuroborreliosis were treated with ceftriaxone (1 x 50-90 mg/kg/day) or penicillin G sodium (4 x 80,000-120,000 IU/kg/day) intravenously. On day 10 of therapy levels of penicillin G sodium (1,1.5,2,3,4, 5, or 6 h after i.v. administration), and ceftriaxone (1,2,4,6,12 or 24 h after i.v. administration) in serum and CSF were measured with a micro agar diffusion bioassay. Results demonstrate that after 5 h penicillin G sodium in CSF was above the minimal inhibitory concentration (MIC) but after 6 h penicillin G sodium levels were below the determination limit in 60% of the cases. All ceftriaxone results in CSF-even after 24 h-were above MIC. Penicillin G sodium serum values ranged from 46.6 to 0.1 mg/L (1 to 6 h post dose) and ceftriaxone serum values from 261 to 5 mg/l (1 to 24 h post dose). The role of penicillin G sodium and ceftriaxone and administration intervals of both antibiotics in the therapy of neuroborreliosis in children are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740117     DOI: 10.1007/bf01713334

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  20 in total

1.  Ceftriaxone pharmacokinetics in the central nervous system.

Authors:  R Spector
Journal:  J Pharmacol Exp Ther       Date:  1986-02       Impact factor: 4.030

2.  Specific immune responses in Lyme borreliosis. Characterization of T cell and B cell responses to Borrelia burgdorferi.

Authors:  R J Dattwyler; D J Volkman; J J Halperin; B J Luft; J Thomas; M G Golightly
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

3.  Pharmacokinetics of ceftriaxone in neonates and infants with meningitis.

Authors:  E Martin; J R Koup; U Paravicini; K Stoeckel
Journal:  J Pediatr       Date:  1984-09       Impact factor: 4.406

4.  Ceftriaxone monotherapy for bacterial meningitis in children.

Authors:  H M Grubbauer; H J Dornbusch; P Dittrich; G Weippl; I Mutz; G Zobel; A Georgopoulos; R Fotter
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

5.  Isolation and characterization of the Lyme disease spirochete from the skin of patients with erythema chronicum migrans.

Authors:  B W Berger; M H Kaplan; I R Rothenberg; A G Barbour
Journal:  J Am Acad Dermatol       Date:  1985-09       Impact factor: 11.527

6.  In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.

Authors:  R C Johnson; C Kodner; M Russell
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

7.  Lyme borreliosis of central nervous system (CNS) in children: a diagnostic challenge.

Authors:  M M Millner; R R Müllegger; K D Spork; G Stanek
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

8.  Facilitated transport of benzylpenicillin through the blood-brain barrier in rats.

Authors:  H Suzuki; Y Sawada; Y Sugiyama; T Iga; M Hanano
Journal:  J Pharmacobiodyn       Date:  1989-03

9.  Ion pair high-performance liquid chromatographic assay for ceftriaxone.

Authors:  G G Granich; D J Krogstad
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

10.  Susceptibility of the Lyme disease spirochete to seven antimicrobial agents.

Authors:  S E Johnson; G C Klein; G P Schmid; J C Feeley
Journal:  Yale J Biol Med       Date:  1984 Jul-Aug
View more
  1 in total

1.  Development of an extrachromosomal cloning vector system for use in Borrelia burgdorferi.

Authors:  M Sartakova; E Dobrikova; F C Cabello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.